6 239

Cited 36 times in

Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

Authors
 Yeo Jue Byun  ;  Mi In Roh  ;  Sung Chul Lee  ;  Hyoung Jun Koh 
Citation
 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, Vol.248(7) : 963-971, 2010 
Journal Title
 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 
ISSN
 0721-832X 
Issue Date
2010
MeSH
Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/administration & dosage* ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/administration & dosage* ; Injections, Intraocular ; Kaplan-Meier Estimate ; Macular Edema/drug therapy* ; Macular Edema/etiology ; Macular Edema/pathology ; Male ; Middle Aged ; Retinal Vein Occlusion/complications ; Retinal Vein Occlusion/drug therapy* ; Retinal Vein Occlusion/pathology ; Retrospective Studies ; Secondary Prevention ; Triamcinolone Acetonide/administration & dosage* ; Visual Acuity/drug effects ; Vitreous Body
Keywords
Bevacizumab ; Branch retinal vein occlusion ; Triamcinolone acetonide
Abstract
PURPOSE: To compare visual outcomes after intravitreal triamcinolone acetonide (IVTA) injection and intravitreal bevacizumab (IVB) administration for treatment of macular edema associated with branch retinal vein occlusion (BRVO). METHODS: A retrospective comparative case series of 134 consecutive patients that were treated with either IVTA or IVB for macular edema caused by BRVO. Visual acuity at baseline and 1, 3, 6, 9, and 12 months, and central macular thickness measured by OCT at baseline and 1, 3, 6, and 12 months. The time to recurrence of macular edema after treatment was also analyzed. RESULTS: Visual acuity (Snellen equivalent) improved significantly from 0.87 logMAR (0.14) to 0.49 logMAR (0.33) in the IVTA group, and from 0.91 logMAR (0.13) to 0.45 logMAR (0.36) in the IVB group 12 months after injection (p < 0.001). Central macular thickness decreased significantly from 491.0 microm to 255.8 microm in the IVTA group, and from 477.4 microm to 218.9 microm in the IVB group 12 months after injection (p < 0.001). In between-group comparisons, neither visual acuity (p = 0.892) nor macular thickness (p = 0.612) improvements were statistically significantly different. In the IVTA-all group, recurrence of macular edema occurred in 7.6% of patients at a mean of 12.6 months postoperatively, and the average number of injections was 1.08. In the IVB-all group, 26.0% of patients suffered recurrences at a mean of 5.3 months after treatment, and received a mean of 1.89 injections. Recurrence was more frequent in the IVB group compared to the IVTA group (Kaplan-Meier survival analysis log-rank test, p < 0.0001). CONCLUSIONS: IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group
Full Text
http://link.springer.com/article/10.1007%2Fs00417-010-1320-2
DOI
10.1007/s00417-010-1320-2
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Koh, Hyoung Jun(고형준) ORCID logo https://orcid.org/0000-0002-5932-8516
Roh, Mi In(노미인)
Byun, Yeo Jue(변여주)
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/101125
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse